Artelo Biosciences Q2 EPS $(0.75) Beats $(0.85) Estimate
Portfolio Pulse from Benzinga Newsdesk
Artelo Biosciences (NASDAQ:ARTL) reported a Q2 EPS of $(0.75), beating the analyst estimate of $(0.85) by 11.76%. This represents a 33.93% increase in losses compared to $(0.56) per share from the same period last year.
August 13, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artelo Biosciences reported a Q2 EPS of $(0.75), beating the analyst estimate of $(0.85) by 11.76%. However, the losses increased by 33.93% compared to the same period last year.
The better-than-expected EPS is a positive sign and may boost investor confidence in the short term. However, the significant increase in losses year-over-year could temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100